Biotechnology Company Amgen filed for U.S. Food and Drug Administration approval of experimental drug denosumab as a treatment for osteoporosis in post- menopausal women.

Generally the FDA aims to make a decision within 10 months of the submission date. Company officials said that the company will find out from the FDA within 60 to 75 days when the agency's review is expected to conclude.

Denosumab also is aimed at preventing and treating the bone-deteriorating condition in patients undergoing breast or prostate cancer treatment.

The company said in September that a large trial of denosumab in post-menopausal women suffering from osteoporosis showed it reduced the risk of some spine fractures by about 68 percent.